期刊
JOURNAL OF CLINICAL NEUROSCIENCE
卷 95, 期 -, 页码 48-54出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.jocn.2021.11.023
关键词
Glioblastoma; Glioblastoma stem cells; Renin-angiotensin system; Renin-angiotensin system inhibitors; Renin-angiotensin system modulators; Drug re-purposing
资金
- Gillies McIndoe Research Institute
This study investigated the tolerability and efficacy of a treatment targeting the renin-angiotensin system (RAS) in patients with glioblastoma. The overall median survival was 19.9 months, and PET/CT scans showed changes in tumor volume and uptake. The treatment was well-tolerated with mild side effects. Further clinical trials are warranted to explore this potential therapeutic option.
Glioblastoma is the most common and most aggressive primary brain cancer in adults. Standard treatment of glioblastoma consisting of maximal safe resection, adjuvant radiotherapy and chemotherapy with temozolomide, results in an overall median survival of 14.6 months. The aggressive nature of glioblastoma has been attributed to the presence of glioblastoma stem cells which express components of the renin-angiotensin system (RAS). This phase I clinical trial investigated the tolerability and efficacy of a treatment targeting the RAS and its converging pathways in patients with glioblastoma. Patients who had relapsed following standard treatment of glioblastoma who met the trial criteria were commenced on dose-escalated oral RAS modulators (propranolol, aliskiren, cilazapril, celecoxib, curcumin with piperine, aspirin, and metformin). Of the 17 patients who were enrolled, ten completed full dose-escalation of the treatment. The overall median survival was 19.9 (95% CI:14.1-25.7) months. Serial FET-PET/CTs showed a reduction in both tumor volume and uptake in one patient, an increase in tumor uptake in nine patients with decreased (n = 1), unchanged (n = 1) and increased (n = 7) tumor volume, in the ten patients who had completed full dose-escalation of the treatment. Two patients experienced mild side effects and all patients had preservation of quality of life and performance status during the treatment. There is a trend towards increased survival by 5.3 months although it was not statistically significant. These encouraging results warrant further clinical trials on this potential novel, well-tolerated and costeffective therapeutic option for patients with glioblastoma. (c) 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据